Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00885-7/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_asco24&_hsenc=p2ANqtz-9rUz-btlp1pIp1vePPJuhaJgfS_xiRWsQFRR9rDLrfm_NIRjdy5wiVBd974T5VQ92ztzZLpTYLisRuVD67iyFvXhCI6g&_hsmi=309962768&utm_content=309962768&utm_source=hs_email